BriaCell Therapeutics

BriaCell Therapeutics Corp. (NASDAQ: BCTX; TSX: BCT) is a clinical-stage immuno-oncology company developing targeted immunotherapies, headquartered in West Vancouver, Canada. Its lead candidate, Bria-IMT, is a targeted immunotherapy in Phase 3 for end-stage breast cancer; the pipeline also includes Bria-OTS and Bria-OTS+, personalized off-the-shelf immunotherapies advanced with an MSK Accelerator collaboration across metastatic breast, prostate, and other cancers, and Bria-MEL+, a personalized whole-cell melanoma immunotherapy vaccine that passed a key genetic engineering milestone in August 2026, clearing the path toward clinical trials. The company holds a University of Maryland Baltimore County license to develop soluble CD80 as an immune-stimulatory biologic and immune checkpoint modulator.